Evidence map›Paper›PMID 30186368›Full record

ArticleTherapeutic advances in urology2018

Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 'real-life' studies.

Michele Marchioni, Petros Sountoulides, Maida Bada, Sebastiano Rapisarda, Cosimo De Nunzio, Fabiola Raffaella Tamburro, Luigi Schips, Luca Cindolo

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Michele MarchioniDepartment of Urology, 'SS Annunziata' Hospital, 'G. D'Annunzio' University of Chieti, Chieti, Italy.
Petros SountoulidesFirst Urology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID https://orcid.org/0000-0003-2671-571X
Maida BadaDepartment of Urology, 'SS Annunziata' Hospital, 'G. D'Annunzio' University of Chieti, Chieti, Italy.
Sebastiano RapisardaDepartment of Urology, Hospital Gaspare Rodolico, Catania, Italy.
Cosimo De NunzioDepartment of Urology, 'Sant'Andrea' Hospital, University La Sapienza, Rome, Italy.
Fabiola Raffaella TamburroDepartment of Urology, ASL Abruzzo2, 'S. Pio da Pietrelcina' Hospital, Vasto, Italy.
Luigi SchipsDepartment of Urology, 'SS Annunziata' Hospital, 'G. D'Annunzio' University of Chieti, Chieti, Italy.
Luca CindoloDepartment of Urology, ASL 2 Abruzzo, 'S. Pio da Pietrelcina' Hospital, Vasto, Italy.
Agenzia Sanitaria Regionale Abruzzo · ITAristotle University of Thessaloniki · GRAzienda Ospedaliera Sant'Andrea · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) in the 'real-life' setting.

methodsData acquisition on the outcomes of the use of AA in chemotherapy-naive patients with mCRPC was performed by a MEDLINE comprehensive systematic literature search using combinations of the following key words: 'prostate cancer', 'metastatic', 'castration resistant', 'abiraterone', 'real life', and excluding controlled clinical trials (phase II and III studies). Identification and selection of the studies was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria. Outcomes of interest were overall survival (OS), progression-free survival (PFS), 12-week 50% reduction in prostate-specific antigen (PSA), and grade 3 and higher adverse events. Data were narratively synthesized in light of methodological and clinical heterogeneity.

resultsWithin the eight identified studies that fulfilled the criteria, a total of 801 patients were included in the meta-analysis. Baseline PSA ranged between 9.5 and 212.0 ng/ml. Most of the patients had bone metastases. Duration of treatment with AA was longer in the studies with lower baseline PSA levels. The median OS ranged between 14 and 36.4 months. The PFS, assessed according to different definitions, ranged from 3.9 to 18.5 months. A 50% PSA reduction at 12 weeks was reached by a variable percentage of patients ranging from 36.0% to 62.1%. Finally, the rate of grade 3 and higher adverse events was reported in three studies and ranged from 4.4% to 15.5%.

conclusionsDespite the high grade of heterogeneity among studies, treatment with AA seems to ensure good survival outcomes in the 'real-life' setting. However, prospective studies based on patients' characteristics being more similar to 'real-life' patients are necessary.

Indexed as

abiraterone acetatechemotherapymetastatic castration-resistant prostate cancerreal-life studies

Identifiers

PMID30186368
PMCPMC6120185
OpenAlexW2818213070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.